Menopause hormone therapy
One RCT (with a moderate risk of bias) in women after breast cancer found a statistically significant improvement in global quality of life for menopause hormone therapy (oestradiol ± progestogen) at 6 and 12 months compared with baseline, but no significant improvement for no menopause hormone therapy compared with baseline; between group differences were not reported.78 Another RCT (with a high risk of bias) found a statistically significant improvement in global quality of life for menopause hormone therapy (sequential or continuous combined oestrogen/progestogen) and electro-acupuncture compared with baseline, but no significant difference between groups.37